Sodium oxybate for excessive daytime sleepiness in Parkinson disease: An open-label polysomnographic study

William G. Ondo, Thomas Perkins, Todd Swick, Keith L. Hull, J. Ernesto Jimenez, Tippy S. Garris, Daniel Pardi

Research output: Contribution to journalArticle

83 Scopus citations

Abstract

Background: Many patients with Parkinson disease (PD) have excessive daytime sleepiness and numerous nocturnal sleep abnormalities. Objective: To determine the safety and efficacy of the controlled drug sodium oxybate in a multicenter, open-label, polysomnographic study in subjects with PD and sleep disorders. Design, Setting, and Patients: Inclusion required an Epworth Sleepiness Scale (ESS) score greater than 10 and any subjective nocturnal sleep concern, usually insomnia. An acclimation and screening polysomnogram was performed to exclude subjects with sleep-disordered breathing. The following evening, subjects underwent another polysomnogram, followed by an evaluation with the Unified Parkinson Disease Rating Scale (UPDRS) while practically defined off ("off") PD medications, ESS (primary efficacy point), Pittsburgh Sleep Quality Inventory, and Fatigue Severity Scale. Subjects then started sodium oxybate therapy, which was titrated from 3 to 9 g per night in split doses (at bedtime and 4 hours later) across 6 weeks, and returned for subjective sleep assessments. They then returned at 12 weeks after initiating therapy for a third polysomnogram, an off-medication UPDRS evaluation, and subjective sleep assessments. Data are expressed as mean (SD). Results: We enrolled 38 subjects. At screening, 8 had sleep apnea (n=7) or depression (n=1). Twenty-seven of 30 subjects completed the study. Three dropped out owing to dizziness (n=3) and concurrent depression (n=1). The mean dose of sodium oxybate was 7.8 (1.7) g per night. The ESS score improved from 15.6 (4.2) to 9.0 (5.0) (P < .001); the Pittsburgh Sleep Quality Inventory score, from 10.9 (4.0) to 6.6 (3.9) (P < .001); and the Fatigue Severity Scale score, from 42.9 (13.2) to 36.3 (14.3) (P < .001). Mean slow-wave sleep time increased from 41.3 (33.2) to 78.0 (61.2) minutes (P = .005). Changes in off-medication UPDRS scores were not significant, from 28.4 (10.3) to 26.2 (9.6). Conclusion: Nocturnally administered sodium oxybate improved excessive daytime sleepiness and fatigue in PD. Trial Registration: clinicaltrials.gov Identifier: NCT00641186.

Original languageEnglish (US)
Pages (from-to)1337-1340
Number of pages4
JournalArchives of neurology
Volume65
Issue number10
DOIs
StatePublished - Oct 2008

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Sodium oxybate for excessive daytime sleepiness in Parkinson disease: An open-label polysomnographic study'. Together they form a unique fingerprint.

Cite this